Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.

Endocrine journal - 1 Jan 2012

Koiou Ekaterini, Tziomalos Konstantinos, Dinas Konstantinos, Katsikis Ilias, Kandaraki Eleni A, Tsourdi Elena, Mavridis Stylianos, Panidis Dimitrios

Abstract excerpt

We aimed to evaluate plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels in women with polycystic ovary syndrome (PCOS) and different levels of adiposity and PCOS phenotypes. We studied 199 women with PCOS and 50 age-matched healthy women divided in normal weight (n=100 and n=25, respectively) and overweight/obese (n=99 and n=25, respectively). Normal weight and overweight/obese patients with PCOS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adiposity
Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperandrogenism

Share to Insulin Resistance

Share to Overweight

Share to Plasminogen Activator Inhibitor 1

Share to Polycystic Ovary Syndrome

Share to Practice Guidelines as Topic

Source

Identifiers

PMID: 21996594
DOI: 10.1507/endocrj.ej11-0023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.PMID 21996594Read ↗

Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes.Semantic proximity Read ↗

The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.Semantic proximity Read ↗

Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome.Semantic proximity Read ↗

The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids.Semantic proximity Read ↗

Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.Semantic proximity Read ↗

The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.Semantic proximity Read ↗

Visceral Adiposity Index (VAI) Levels in Patients with Different Phenotypes of Polycystic Ovary Syndrome (PCOS)Semantic proximity Read ↗

Body Mass Index below Obesity Threshold Implies Similar Cardiovascular Risk among Various Polycystic Ovary Syndrome Phenotypes.Semantic proximity Read ↗

Visceral Adiposity Index in Relation to Rotterdam Phenotypes of Polycystic Ovary SyndromeSemantic proximity Read ↗

Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.Semantic proximity Read ↗

The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.